---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-110169"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T02:04:51.912350+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MoonLake director resigns; CEO, CSO, CFO each to receive $4M equity grants in Jan 2025

## Summary
- Dr. Kara Lassen resigns from Board effective Dec 31, 2024, due to new role at Roche Pharma; no dispute with Company.
- Board approved long-term incentive program with annual equity grants; employees may elect restricted stock awards or stock options.
- CEO Dr. Jorge Santos da Silva, CSO Dr. Kristian Reich, and CFO Matthias Bodenstedt each expected to receive $4M grant date fair value in Jan 2025, vesting over four years.
- Board size reduced from 7 to 6 directors following resignation.

## SEC filing metadata
- accession: 0001213900-24-110169
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390024110169/0001213900-24-110169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390024110169/ea0225122-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-110169
- JSON: https://secwatch.observer/filing/0001213900-24-110169.json
- Plain text: https://secwatch.observer/filing/0001213900-24-110169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.